RNA vs LLY

For growth investors, Atrium Therapeutics, Inc.

(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus 44. 7% for Eli Lilly and Company (LLY). Eli Lilly and Company (LLY) offers the better valuation at 49. 2x trailing P/E (30. 9x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +416.

5%, compared to -51. 5% for Atrium Therapeutics, Inc. (RNA). Over 10 years, the gap is even starker: LLY returned +1483% versus RNA's -55. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

53β versus Atrium Therapeutics, Inc. 's 1. 38β — meaning RNA is approximately 162% more volatile than LLY relative to the S&P 500. On balance sheet safety, Atrium Therapeutics, Inc. (RNA) carries a lower debt/equity ratio of 2% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atrium Therapeutics, Inc.

(RNA) is pulling ahead at 70. 9% versus 44. 7% for Eli Lilly and Company (LLY). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -55. 0% for Atrium Therapeutics, Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RNA: 96.

1% to $25. 00.

In this comparison, LLY (0.

5% yield) pays a dividend. RNA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1483% 10Y return). Both have compounded well over 10 years (LLY: +1483%, RNA: -55. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LLY pays a dividend while RNA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.